Test Name Results Units Bio. Ref. Interval

Transcription

1 LL - LL-ROHINI (NATIONAL REFERENCE Age 37 Years Gender Male 29/8/ AM 29/8/ AM 29/8/ AM Ref By Final COAGULATION ROFILE 1 ARTIAL THROMBOLASTIN TIME, ACTIVATED; ATT (hoto optical Clot Detection) atient Value sec Control Value sec 1. Degree of prolongation of TT / ATT is neither predictive of bleeding risk nor underlying diagnosis 2. Results should be clinically correlated 3. Test conducted on Citrated plasma artial Thromboplastin time (TT / ATT) measures the proteins of the intrinsic coagulation pathway which consists of Factor XII, rekallikrein, High molecular weight kininogen, Factors VIII, IX & XI. It also measures proteins of the common pathway namely factors II, V, X & Fibrinogen. TT is prolonged when Factor VIII level is < of normal and Factor XII & High molecular weight kininogen is < of normal. Abnormal artial Thromboplastin Time Associated with bleeding Defects of factors VIII, IX & XI Not associated with bleeding Defects of factor XII, rekallikrein, High molecular weight kininogen & Lupus anticoagulants Causes of prolonged TT / ATT Liver disease Consumptive coagulopathy Circulating anticoagulants including Lupus Anticoagulant Oral Anticoagulant therapy Factor deficiencies ROTHROMBIN TIME STUDIES (hoto optical Clot Detection) Mean Normal rothrombin Time (T) sec <10.70 atientreportscsuperanel.s_general_temlate01_sc (Version 7) age 1 of 5

2 LL - LL-ROHINI (NATIONAL REFERENCE Age 37 Years Gender Male 29/8/ AM 29/8/ AM 29/8/ AM Ref By Final atient value sec rothrombin Ratio (R) 1.00 International Normalized Ratio (INR) INR is the parameter of choice in monitoring adequacy of oral anticoagulant therapy. Appropriate therapeutic range varies with the disease and treatment intensity 2. rolonged INR suggests potential bleeding disorder / bleeding complications 3. Results should be clinically correlated 4. Test conducted on Citrated plasma Recommended Therapeutic range for Oral Anticoagulant therapy INR INR Treatment of Venous thrombosis & ulmonary embolism rophylaxis of Venous thrombosis (High risk surgery) revention of systemic embolism in tissue heart valves, AMI, Valvular heart disease & Atrial fibrillation Bileaflet mechanical valve in aortic position Mechanical prosthetic valves Systemic recurrent emboli rothrombin time measures the extrinsic coagulation pathway which consists of activated Factor VII (VIIa), Tissue factor and roteins of the common pathway (Factors X, V, II & Fibrinogen). This assay is used to control long term oral anticoagulant therapy, evaluation of liver function & to evaluate coagulation disorders specially factors involved in the extrinsic pathway like Factors V, VII, X, rothrombin & Fibrinogen. THROMBIN TIME; TT (Electromechanical Clot Detection) atient Value sec <21.00 Control Value sec Thrombin Time should be interpreted in conjunction with other coagulation assays like T & atientreportscsuperanel.s_general_temlate01_sc (Version 7) age 2 of 5

3 LL - LL-ROHINI (NATIONAL REFERENCE Age 37 Years Gender Male 29/8/ AM 29/8/ AM 29/8/ AM Ref By Final ATT to enhance diagnostic value. 2. Results should be clinically correlated. 3. Test conducted on Citrated plasma. Thrombin Time (TT) measures the ability of exogenous thrombin to proteolyse fibrinogen. Thus it is used to characterize fibrinogen function. It is prolonged in conditions like hypofibrinogenemia, dysfibrinogenemia, presence of fibrin degradation products, antibody inhibitors of thrombin and in conditions with high concentrations of monoclonal immunoglobulins which interfere with fibrin monomer polymerization like Myeloma & Macroglobulinemia. BLEEDING TIME; BT # (Ivy's Method) 2.00 minutes 2-7 CLOTTING TIME; CT # (Lee & White) 5.00 minutes 3-10 Recommended test is rothrombin Time (T) and Activated artial Thromboplastin time (ATT) atientreportscsuperanel.s_general_temlate01_sc (Version 7) age 3 of 5

4 LL - LL-ROHINI (NATIONAL REFERENCE Age 37 Years Gender Male 29/8/ AM 29/8/ AM 29/8/ AM Ref By Final COMLETE BLOOD COUNT (CBC) (Electrical Impedance & VCS,hotometry ) Hemoglobin g/dl acked Cell Volume (CV) RBC Count 4.16 mill/mm MCV fl MCH pg MCHC g/dl Red Cell Distribution Width (RDW) Total Leukocyte Count (TLC) Differential Leucocyte Count (DLC) Segmented Neutrophils Lymphocytes Monocytes Eosinophils 1.00 Basophils 0.60 Absolute Leucocyte Count <2.00 Neutrophils Lymphocytes Monocytes Eosinophils Basophils latelet Count As per the recommendation of International council for Standardization in Hematology, the differential leucocyte counts are additionally being reported as absolute numbers of each cell in per unit volume of blood 2. Test conducted on EDTA whole blood age 4 of 5

5 LL - LL-ROHINI (NATIONAL REFERENCE Age 37 Years Gender Male 29/8/ AM 29/8/ AM 29/8/ AM Ref By Final Dr. Anil Arora MD (athology) HOD Hemat & Imm Dr Biswadip Hazarika MD (athology) Sr. Consultant athologist End of report age 5 of 5